Retrovirus screening of vaccine cell substrates
Related Experiment Video
Updated: Sep 20, 2026

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
Published on: August 1, 2013
1Division of Viral Products, FDA, Bethesda, MD, USA.
Abstract:
A strategy for the detection of low levels of infectious retroviruses in vaccine cell substrates is outlined. This strategy involves amplification of possible viral contaminants in cell substrates by co-cultivation of the Cell Bank, with or without prior induction, with potentially susceptible cells followed by extended culturing and subsequent retrovirus testing using general and specific detection assays. In some cases, the virus seed may need to be examined by direct infection and extended culturing of cells that can support the replication of potential retroviral contaminants.

